In contrast to the OE19 xenografts, trastuzumab treatment resulted in modest, but not statistically significant tumour growth inhibition of Eso26 tumour xenografts during the full time course of the treatment, while GRB7 knockdown alone or in combination with trastuzumab had significant anti‐tumour activity compared with the vehicle treatment group (Figure 6G,H). This evidence concerns the gene GRB7 and neoplasm.